JP2018513680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513680A5 JP2018513680A5 JP2017549723A JP2017549723A JP2018513680A5 JP 2018513680 A5 JP2018513680 A5 JP 2018513680A5 JP 2017549723 A JP2017549723 A JP 2017549723A JP 2017549723 A JP2017549723 A JP 2017549723A JP 2018513680 A5 JP2018513680 A5 JP 2018513680A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- hbv
- binding
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 109
- 241000700721 Hepatitis B virus Species 0.000 claims description 91
- 239000000427 antigen Substances 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 56
- 108091007433 antigens Proteins 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 46
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 40
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 230000002458 infectious effect Effects 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 11
- 208000006454 hepatitis Diseases 0.000 claims description 10
- 230000003389 potentiating effect Effects 0.000 claims description 9
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010019663 Hepatic failure Diseases 0.000 claims description 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 3
- 231100000354 acute hepatitis Toxicity 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 231100000835 liver failure Toxicity 0.000 claims description 3
- 208000007903 liver failure Diseases 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 101710132601 Capsid protein Proteins 0.000 claims description 2
- 208000037319 Hepatitis infectious Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000007485 viral shedding Effects 0.000 description 2
- 102400001107 Secretory component Human genes 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562137881P | 2015-03-25 | 2015-03-25 | |
| US62/137,881 | 2015-03-25 | ||
| PCT/US2016/024348 WO2016154593A1 (en) | 2015-03-25 | 2016-03-25 | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513680A JP2018513680A (ja) | 2018-05-31 |
| JP2018513680A5 true JP2018513680A5 (enExample) | 2019-05-09 |
| JP6882184B2 JP6882184B2 (ja) | 2021-06-02 |
Family
ID=56977811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549723A Expired - Fee Related JP6882184B2 (ja) | 2015-03-25 | 2016-03-25 | 多価ｂ型肝炎ウイルス抗原結合分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10604559B2 (enExample) |
| EP (1) | EP3274051A4 (enExample) |
| JP (1) | JP6882184B2 (enExample) |
| KR (1) | KR102558839B1 (enExample) |
| CN (1) | CN107921285B (enExample) |
| AU (1) | AU2016238246B2 (enExample) |
| CA (1) | CA2980751A1 (enExample) |
| WO (1) | WO2016154593A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105722855B (zh) | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| KR102378289B1 (ko) | 2014-02-10 | 2022-03-23 | 아이쥐엠 바이오사이언스 인코포레이티드 | IgA 다중-특이적 결합 분자 |
| CN112759650B (zh) | 2014-04-03 | 2024-10-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| CA2972990A1 (en) | 2015-01-20 | 2016-07-28 | Beatrice Tien-Yi WANG | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| NZ762365A (en) | 2015-03-04 | 2024-11-29 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| PL3355913T3 (pl) | 2015-09-30 | 2025-02-17 | Igm Biosciences, Inc. | Cząsteczki wiążące ze zmodyfikowanym łańcuchem j |
| WO2017059387A1 (en) | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
| DK3455257T3 (da) | 2016-05-09 | 2021-11-01 | Igm Biosciences Inc | Anti-pd-l1-antistoffer |
| KR102696143B1 (ko) | 2017-04-07 | 2024-08-21 | 아이쥐엠 바이오사이언스 인코포레이티드 | 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 |
| MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| EP3870223A4 (en) * | 2018-10-23 | 2022-08-24 | IGM Biosciences, Inc. | MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES |
| US20230250192A1 (en) * | 2019-05-15 | 2023-08-10 | Kymab Limited | Improved lambda antibodies |
| CA3147291A1 (en) | 2019-08-15 | 2021-02-18 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| EP4139362A2 (en) | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
| EP4188951A4 (en) * | 2020-07-27 | 2024-08-28 | IGM Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| KR102674098B1 (ko) * | 2021-01-14 | 2024-06-12 | (주)옵토레인 | 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법 |
| US20240209068A1 (en) * | 2021-04-01 | 2024-06-27 | Modernatx, Inc. | Mucosal expression of antibody structures and isotypes by mrna |
| WO2022265264A1 (ko) * | 2021-06-15 | 2022-12-22 | 에이피트바이오 주식회사 | B형 간염바이러스 pres1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도 |
| US20240391979A1 (en) * | 2021-09-13 | 2024-11-28 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| CN116640208B (zh) * | 2023-06-01 | 2025-02-07 | 重庆医科大学 | 一种乙肝核心抗原单链抗体噬菌体文库及其构建与应用 |
| CN117624340B (zh) * | 2024-01-23 | 2024-04-30 | 北京臻知医学科技有限责任公司 | 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4433059A (en) * | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| JPS6358260A (ja) * | 1986-08-29 | 1988-03-14 | Chemo Sero Therapeut Res Inst | ＩｇＭ型抗体の測定法 |
| US5061619A (en) * | 1987-11-05 | 1991-10-29 | Connaught Laboratories Limited | Immunoassay using antibody-antigen conjugates |
| CA2064972A1 (en) | 1991-04-03 | 1992-10-04 | John Joseph Rejman | Immunoassay for immunoglobulins |
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| US6417324B1 (en) * | 2000-04-21 | 2002-07-09 | Tripep Ab | Synthetic peptides that bind to the hepatitis B virus core and e antigens |
| GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
| US6063905A (en) * | 1997-01-07 | 2000-05-16 | Board Of Regents, The University Of Texas System | Recombinant human IGA-J. chain dimer |
| KR100345463B1 (ko) | 1998-11-19 | 2003-01-08 | 주)녹십자 | B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법 |
| CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| ATE490787T1 (de) * | 2003-07-15 | 2010-12-15 | Chugai Pharmaceutical Co Ltd | Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion |
| CN1600856A (zh) * | 2003-09-26 | 2005-03-30 | 陕西九州科技股份有限公司 | 分泌抗乙肝人单克隆抗体的异种杂交瘤细胞系的构建方法 |
| AU2005304973A1 (en) | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
| ATE529436T1 (de) | 2007-04-20 | 2011-11-15 | Hoffmann La Roche | Erkennung von primären infektionen mit krankheitserregern |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| CN102321720B (zh) * | 2011-07-28 | 2014-09-03 | 万晓春 | 一种混合细胞培养生产纯人源单克隆抗体的方法 |
| EP2760891B1 (en) | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| ES2735289T3 (es) | 2012-02-08 | 2019-12-17 | Igm Biosciences Inc | Proteínas de unión a cdim y usos de las mismas |
| JP2015524821A (ja) * | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
| KR20150070181A (ko) | 2012-09-27 | 2015-06-24 | 크루셀 홀란드 비.브이. | B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도 |
| CN105722855B (zh) | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| SG11201605691VA (en) | 2014-01-16 | 2016-08-30 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
| KR102378289B1 (ko) | 2014-02-10 | 2022-03-23 | 아이쥐엠 바이오사이언스 인코포레이티드 | IgA 다중-특이적 결합 분자 |
| CN112759650B (zh) | 2014-04-03 | 2024-10-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| CA2972990A1 (en) | 2015-01-20 | 2016-07-28 | Beatrice Tien-Yi WANG | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| NZ762365A (en) * | 2015-03-04 | 2024-11-29 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| PL3355913T3 (pl) | 2015-09-30 | 2025-02-17 | Igm Biosciences, Inc. | Cząsteczki wiążące ze zmodyfikowanym łańcuchem j |
| WO2017059387A1 (en) | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
| DK3455257T3 (da) | 2016-05-09 | 2021-11-01 | Igm Biosciences Inc | Anti-pd-l1-antistoffer |
| EP3487298A4 (en) | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF |
| WO2018017763A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| MX2019000796A (es) | 2016-07-20 | 2019-06-03 | Igm Biosciences Inc | Moleculas multimericas de union a ox40 y usos de las mismas. |
| AU2017300647A1 (en) | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric GITR binding molecules and uses thereof |
| KR102696143B1 (ko) | 2017-04-07 | 2024-08-21 | 아이쥐엠 바이오사이언스 인코포레이티드 | 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 |
| CN111757941A (zh) | 2018-02-26 | 2020-10-09 | Igm生物科学股份有限公司 | 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 |
| MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| EP3870223A4 (en) | 2018-10-23 | 2022-08-24 | IGM Biosciences, Inc. | MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES |
| WO2020163646A1 (en) | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| CA3147291A1 (en) | 2019-08-15 | 2021-02-18 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| WO2021034646A1 (en) | 2019-08-17 | 2021-02-25 | Igm Biosciences, Inc. | Multimeric bispecific anti-cd123 binding molecules and uses thereof |
| US20220306760A1 (en) | 2019-08-23 | 2022-09-29 | Igm Biosciences, Inc. | Igm glycovariants |
| WO2021055765A2 (en) | 2019-09-19 | 2021-03-25 | Igm Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| KR20220122699A (ko) | 2020-01-06 | 2022-09-02 | 아이쥐엠 바이오사이언스 인코포레이티드 | 고도로 시알릴화된 다량체 결합 분자 |
| EP4139362A2 (en) | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
| JP2023526224A (ja) | 2020-05-12 | 2023-06-21 | アイジーエム バイオサイエンシズ インコーポレイテッド | がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用 |
| EP4188951A4 (en) | 2020-07-27 | 2024-08-28 | IGM Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| US20240002526A1 (en) | 2020-11-17 | 2024-01-04 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
-
2016
- 2016-03-25 WO PCT/US2016/024348 patent/WO2016154593A1/en not_active Ceased
- 2016-03-25 JP JP2017549723A patent/JP6882184B2/ja not_active Expired - Fee Related
- 2016-03-25 US US15/560,905 patent/US10604559B2/en active Active
- 2016-03-25 KR KR1020177030451A patent/KR102558839B1/ko active Active
- 2016-03-25 AU AU2016238246A patent/AU2016238246B2/en not_active Ceased
- 2016-03-25 CA CA2980751A patent/CA2980751A1/en active Pending
- 2016-03-25 EP EP16769812.5A patent/EP3274051A4/en not_active Withdrawn
- 2016-03-25 CN CN201680029323.0A patent/CN107921285B/zh not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/795,433 patent/US11535664B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513680A5 (enExample) | ||
| JP6882184B2 (ja) | 多価ｂ型肝炎ウイルス抗原結合分子およびその使用 | |
| JP2010518854A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| CN103841993A (zh) | 人肠道病毒特异性抗体及其在诊断中的应用 | |
| CA3001231A1 (en) | Antibody against hepatitis b surface antigen and use thereof | |
| CN104220090A (zh) | 肠道病毒71型的特异性抗体及其用途 | |
| JP2018537117A5 (enExample) | ||
| CN110294802B (zh) | 一种单克隆抗体10g12及其应用 | |
| JP2025504537A (ja) | Ｈｂｖ感染及び関連疾患の治療のためのエピトープペプチド及び抗体 | |
| CN111018989B (zh) | 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用 | |
| JP7372638B2 (ja) | 抗ｂ型肝炎ウイルス抗体及びその使用 | |
| CN105085672A (zh) | 3d蛋白特异性单克隆免疫球蛋白a抗体及其组合物 | |
| JPWO2020130138A5 (enExample) | ||
| RU2803082C2 (ru) | Антитела против вируса гепатита в и их применение | |
| Vianna et al. | Evaluation of murine monoclonal antibodies targeting different epitopes of the hepatitis B virus surface antigen by using immunological as well as molecular biology and biochemical approaches | |
| CN107286237A (zh) | 一种抗丙型肝炎病毒抗体的获取以及应用 | |
| WO2022025129A1 (ja) | 新規な抗ＨＢｓ免疫グロブリンの製造方法 | |
| HK40068830A (en) | Anti-hepatitis b virus antibodies and use thereof | |
| WO2015037992A1 (en) | Parechovirus specific antibodies |